Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: CON

Overview

Journal Kidney360

Specialty Nephrology

Date 2022 Apr 4

PMID 35368625

Authors

Victoria Gutgarts

Ilya G Glezerman

Affiliations

Soon will be listed here.

Citing Articles

Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor-induced kidney disease.

Seethapathy H, Mistry K, Sise M Immunol Rev. 2023; 318(1):61-69.

PMID: 37482912 PMC: 10865966. DOI: 10.1111/imr.13243.

Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.

Muto S, Matsubara T, Inoue T, Kitamura H, Yamamoto K, Ishii T Int J Clin Oncol. 2023; 28(10):1259-1297.

PMID: 37382749 DOI: 10.1007/s10147-023-02372-4.

Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge.

Catalano M, Roviello G, Galli I, Santi R, Nesi G Front Med (Lausanne). 2023; 9:1014257.

PMID: 36606052 PMC: 9807763. DOI: 10.3389/fmed.2022.1014257.

Acute Kidney Injury in Cancer Immunotherapy Recipients.

Joseph A, Lafarge A, Azoulay E, Zafrani L Cells. 2022; 11(24).

PMID: 36552755 PMC: 9776910. DOI: 10.3390/cells11243991.

Nephrotoxicity of Immune Checkpoint Inhibitors: Acute Kidney Injury and Beyond.

Tinawi M, Bastani B Cureus. 2021; 12(12):e12204.

PMID: 33489613 PMC: 7817088. DOI: 10.7759/cureus.12204.

References

Izzedine H, Mathian A, Champiat S, Picard C, Mateus C, Routier E . Renal toxicities associated with pembrolizumab. Clin Kidney J. 2019; 12(1):81-88. PMC: 6366307. DOI: 10.1093/ckj/sfy100. View

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

Shirali A, Perazella M, Gettinger S . Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. Am J Kidney Dis. 2016; 68(2):287-291. DOI: 10.1053/j.ajkd.2016.02.057. View

Wanchoo R, Karam S, Uppal N, Barta V, Deray G, Devoe C . Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. Am J Nephrol. 2017; 45(2):160-169. DOI: 10.1159/000455014. View

Seethapathy H, Zhao S, Chute D, Zubiri L, Oppong Y, Strohbehn I . The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. Clin J Am Soc Nephrol. 2019; 14(12):1692-1700. PMC: 6895474. DOI: 10.2215/CJN.00990119. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

Cortazar F, Kibbelaar Z, Glezerman I, Abudayyeh A, Mamlouk O, Motwani S . Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. J Am Soc Nephrol. 2020; 31(2):435-446. PMC: 7003302. DOI: 10.1681/ASN.2019070676. View

Haslam A, Prasad V . Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open. 2019; 2(5):e192535. PMC: 6503493. DOI: 10.1001/jamanetworkopen.2019.2535. View

Cassol C, Satoskar A, Lozanski G, Rovin B, Hebert L, Nadasdy T . Anti-PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1. Kidney Int Rep. 2019; 4(8):1152-1160. PMC: 6698303. DOI: 10.1016/j.ekir.2019.06.001. View

10.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Cowey C, Lao C . Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(1):23-34. PMC: 5698905. DOI: 10.1056/NEJMoa1504030. View

11.

Khalili H, Bairami S, Kargar M . Antibiotics induced acute kidney injury: incidence, risk factors, onset time and outcome. Acta Med Iran. 2014; 51(12):871-8. View

12.

Haanen J, Carbonnel F, Robert C, Kerr K, Peters S, Larkin J . Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv119-iv142. DOI: 10.1093/annonc/mdx225. View

13.

Shingarev R, Glezerman I . Kidney Complications of Immune Checkpoint Inhibitors: A Review. Am J Kidney Dis. 2019; 74(4):529-537. PMC: 6756976. DOI: 10.1053/j.ajkd.2019.03.433. View

14.

Dixit M, Doan T, Kirschner R, Dixit N . Significant Acute Kidney Injury Due to Non-steroidal Anti-inflammatory Drugs: Inpatient Setting. Pharmaceuticals (Basel). 2016; 3(4):1279-1285. PMC: 4034033. DOI: 10.3390/ph3041279. View

15.

Brachemi S, Bollee G . Renal biopsy practice: What is the gold standard?. World J Nephrol. 2014; 3(4):287-94. PMC: 4220363. DOI: 10.5527/wjn.v3.i4.287. View

16.

Latcha S, Jaimes E, Patil S, Glezerman I, Mehta S, Flombaum C . Long-Term Renal Outcomes after Cisplatin Treatment. Clin J Am Soc Nephrol. 2016; 11(7):1173-1179. PMC: 4934839. DOI: 10.2215/CJN.08070715. View

17.

Blank M, Parkin L, Paul C, Herbison P . A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014; 86(4):837-44. PMC: 4184187. DOI: 10.1038/ki.2014.74. View

18.

Brahmer J, Lacchetti C, Schneider B, Atkins M, Brassil K, Caterino J . Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018; 36(17):1714-1768. PMC: 6481621. DOI: 10.1200/JCO.2017.77.6385. View

19.

Brewster U, Perazella M . Proton pump inhibitors and the kidney: critical review. Clin Nephrol. 2007; 68(2):65-72. DOI: 10.5414/cnp68065. View

20.

Postow M, Sidlow R, Hellmann M . Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018; 378(2):158-168. DOI: 10.1056/NEJMra1703481. View